Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Myriad Genetics is nearing completion of the preclinical stage in the development of MPC-0920, its anti-clotting drug candidate, for submission to the FDA prior to beginning human clinical trials.
Subscribe to our email newsletter
MPC-0920 is an orally available, direct thrombin inhibitor. It is designed to address the clinical needs for rapid and predictable anticoagulant action, an improved therapeutic window, predictable patient response and increased efficacy.
MPC-0920 has been the subject of 27 preclinical studies to date, comprising safety, toxicity, pharmacokinetics and formulation.
“MPC-0920 is an intriguing compound in a vitally important therapeutic area,” said Dr Adrian Hobden, President of Myriad Pharmaceuticals. “We look forward to completing the preclinical data package for submission to the FDA this fiscal year.”
According to the company, the total market for medicines to treat thrombotic disorders in 2003 was $6.5 billion.